Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty - PubMed (original) (raw)
Clinical Trial
. 2000 Jan 20;11(2):263-70.
doi: 10.1089/10430340050016003.
J Hartikainen, M O Hiltunen, J Eränen, M Kiviniemi, O Närvänen, K Mäkinen, H Manninen, M Syvänne, J F Martin, M Laakso, S Ylä-Herttuala
Affiliations
- PMID: 10680840
- DOI: 10.1089/10430340050016003
Clinical Trial
Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty
M Laitinen et al. Hum Gene Ther. 2000.
Abstract
Blood vessels are among the easiest targets for gene therapy. However, no data are available about the safety and feasibility of intracoronary gene transfer in humans. We studied the safety and efficacy of catheter-mediated vascular endothelial growth factor (VEGF) plasmid/liposome (P/L) gene transfer in human coronary arteries after percutaneous translumenal coronary angioplasty (PTCA) in a randomized, double-blinded, placebo-controlled study. The optimized angioplasty/gene delivery method was previously shown to lead to detectable VEGF gene expression in human peripheral arteries as analyzed from amputated leg samples. Gene transfer to coronary arteries was done with a perfusion-infusion catheter, using 1000 microg of VEGF or beta-galactosidase plasmid complexed with 1000 microl of DOTMA:DOPE liposomes. Ten patients received VEGF P/L, three patients received beta-galactosidase P/L, and two patients received Ringer lactate. Gene transfer to coronary arteries was feasible and well tolerated. Except for a slight increase in serum C-reative protein in all study groups, no adverse effects or abnormalities in laboratory parameters were detected. No VEGF plasmid or recombinant VEGF protein was present in the systemic circulation after the gene transfer. In control angiography 6 months later, no differences were detected in the degree of coronary stenosis between treatment and control groups. We conclude that catheter-mediated intracoronary gene transfer performed after angioplasty is safe and well tolerated and potentially applicable for the prevention of restenosis and myocardial ischemia.
Similar articles
- Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT).
Hedman M, Hartikainen J, Syvänne M, Stjernvall J, Hedman A, Kivelä A, Vanninen E, Mussalo H, Kauppila E, Simula S, Närvänen O, Rantala A, Peuhkurinen K, Nieminen MS, Laakso M, Ylä-Herttuala S. Hedman M, et al. Circulation. 2003 Jun 3;107(21):2677-83. doi: 10.1161/01.CIR.0000070540.80780.92. Epub 2003 May 12. Circulation. 2003. PMID: 12742981 Clinical Trial. - Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study.
Mäkinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E, Ylä-Herttuala S. Mäkinen K, et al. Mol Ther. 2002 Jul;6(1):127-33. doi: 10.1006/mthe.2002.0638. Mol Ther. 2002. PMID: 12095313 Clinical Trial. - Vascular endothelial growth factor (VEGF165) and its influence on angiogenesis versus arteriogenesis in different vascular beds.
Nikol S, Pelisek J, Engelmann MG, Shimizu M, Fuchs A, Golda A, Armeanu S, Mekkaoui C, Rolland PH. Nikol S, et al. J Endovasc Ther. 2002 Dec;9(6):842-54. doi: 10.1177/152660280200900619. J Endovasc Ther. 2002. PMID: 12546587 - Gene therapy for myocardial angiogenesis.
Losordo DW, Vale PR, Isner JM. Losordo DW, et al. Am Heart J. 1999 Aug;138(2 Pt 2):S132-41. doi: 10.1016/s0002-8703(99)70333-9. Am Heart J. 1999. PMID: 10426872 Review. - [Gene therapy with VEGF].
Maillard L, Peycher P, Fichaux O, Vincentelli-Djeffal D. Maillard L, et al. Presse Med. 2000 Oct 21;29(31):1731-7. Presse Med. 2000. PMID: 11094621 Review. French.
Cited by
- Cloning and identification of a novel variant of human vascular endothelial growth factor.
Guo J, Qu S. Guo J, et al. J Tongji Med Univ. 2001;21(3):191-4. doi: 10.1007/BF02886426. J Tongji Med Univ. 2001. PMID: 12539573 - In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.
Audouy SA, de Leij LF, Hoekstra D, Molema G. Audouy SA, et al. Pharm Res. 2002 Nov;19(11):1599-605. doi: 10.1023/a:1020989709019. Pharm Res. 2002. PMID: 12458664 Review. - Targeted gene therapy for the treatment of heart failure.
Rapti K, Chaanine AH, Hajjar RJ. Rapti K, et al. Can J Cardiol. 2011 May-Jun;27(3):265-83. doi: 10.1016/j.cjca.2011.02.005. Can J Cardiol. 2011. PMID: 21601767 Free PMC article. Review. - Gene targeting in ischemic heart disease and failure: translational and clinical studies.
Eckhouse SR, Jones JA, Spinale FG. Eckhouse SR, et al. Biochem Pharmacol. 2013 Jan 1;85(1):1-11. doi: 10.1016/j.bcp.2012.08.018. Epub 2012 Aug 28. Biochem Pharmacol. 2013. PMID: 22935384 Free PMC article. Review. - The mechanical study of vascular endothelial growth factor on the prevention of restenosis after angioplasty.
Liu Q, Lu Z, Zhou H, Yan J, Zhang W. Liu Q, et al. J Tongji Med Univ. 2001;21(3):195-7. doi: 10.1007/BF02886427. J Tongji Med Univ. 2001. PMID: 12539574
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical